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Abstract
 
DNAX accessory molecule 1 (DNAM-1; CD226) is a transmembrane glycoprotein involved
in T cell and natural killer (NK) cell cytotoxicity. We demonstrated recently that DNAM-1
triggers NK cell–mediated killing of tumor cells upon engagement by its two ligands, poliovi-
rus receptor (PVR; CD155) and Nectin-2 (CD112). In the present paper, we show that PVR
and Nectin-2 are expressed at cell junctions on primary vascular endothelial cells. Moreover,
the specific binding of a soluble DNAM-1–Fc molecule was detected at endothelial junctions.
This binding was almost completely abrogated by anti-PVR monoclonal antibodies (mAbs),
but not modified by anti–Nectin-2 mAbs, which demonstrates that PVR is the major DNAM-1
ligand on endothelial cells. Because DNAM-1 is highly expressed on leukocytes, we investi-
gated the role of the DNAM-1–PVR interaction during the monocyte transendothelial migra-
tion process. In vitro, both anti–DNAM-1 and anti-PVR mAbs strongly blocked the transmi-
gration of monocytes through the endothelium. Moreover, after anti–DNAM-1 or anti-PVR
mAb treatment, monocytes were arrested at the apical surface of the endothelium over inter-
cellular junctions, which strongly suggests that the DNAM-1–PVR interaction occurs during
the diapedesis step. Altogether, our results demonstrate that DNAM-1 regulates monocyte ex-
travasation via its interaction with PVR expressed at endothelial junctions on normal cells.
Key words: CD226 • CD155 • Nectin • endothelium • diapedesis
 
Introduction
 
DNAX accessory molecule 1 (DNAM-1; CD226) is a
transmembrane glycoprotein member of the immunoglob-
ulin superfamily. In humans, it is constitutively expressed
on a subset of B lymphocytes and on all T lymphocytes,
NK cells, monocytes, and platelets (1). mAb-mediated
cross-linking of DNAM-1 enhances the triggering of both
T and NK cell cytotoxicity (1). We demonstrated recently
that DNAM-1 specifically recognizes two cellular ligands
named poliovirus receptor (PVR; CD155) and Nectin-2
(CD112). Tumor target cells frequently coexpress both
PVR and Nectin-2, whereas they display low levels of
HLA class I molecules. Upon engagement by these ligands,
DNAM-1 was shown to induce NK cell–mediated cyto-
toxicity (2), and its involvement in the NK cell–mediated
lysis strictly correlated with the expression of PVR and
Nectin-2 on tumor cells (2). PVR and Nectin-2 are mem-
bers of the Nectin family that also belongs to the immuno-
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globulin superfamily. In humans, this family comprises five
structurally related molecules as follows: PVR (3), Nec-
tin-1, -2, -3, and -4 (4–7). Both PVR and Nectin-2 are acces-
sory receptors for some 
 
 
 
 herpesviruses (3, 8, 9). Nectins
have been shown to play a fundamental role during the es-
tablishment of cell polarity and in the regulation of inter-
cellular junctions in epithelial and neuronal cells (10).
They are involved in the formation of both adherens and
tight junctions in epithelial cells (10). Nectins recruit, reg-
ulate, and interact with E-cadherin at adherens junctions
(AJs) via their cytoplasmic associated molecules (i.e.,
AF-6/afadin and catenins, respectively; reference 11).
Also, they recruit and target junctional adhesion molecule
(JAM)-A during the formation of tight junctions (10).
They assume their functions by mediating homophilic and
heterophilic transinteractions following defined combina-
tions; among them, PVR and Nectin-2 both interact with
Nectin-3 (2, 7) and DNAM-1 (2). Nectin-2 was also
shown to display homophilic adhesion on endothelial cells
(12).
PVR and Nectin-2 are not tumor-specific antigens be-
cause they are widely expressed on normal cells including
neuronal, epithelial, endothelial, and fibroblastic cells (13).
Thus, in an autologous setting, DNAM-1 interaction with
PVR and Nectin-2 does not result in NK cell–mediated
lysis of normal cells. Indeed, these latter express normal
levels of self-HLA class I molecules that block the NK cell
function upon interaction with inhibitory NK receptors
(14). Recently, a new DNAM-1 function has been pro-
posed during platelet aggregation (15). From all these data,
we speculated that DNAM-1 interaction with PVR and/
or Nectin-2 expressed on endothelial cells may take part
in cellular transmigration through endothelial cells. Leu-
kocytes escape the blood circulation by interacting with
the endothelial cells of the vessel walls from blood to sec-
ondary lymphoid organs or underlying tissues through a
well-characterized multistep adhesion molecule cascade
(16–21). Although actors involved in the first steps of
tethering and rolling are well established, less is known
about the late phase of diapedesis. Herein, we show that
both PVR and Nectin-2 are expressed at vascular interen-
dothelial junctions and demonstrate that PVR is the major
DNAM-1 ligand on endothelial cells. Finally, by using
human monocytes that highly expressed DNAM-1, we
provide evidence that DNAM-1 interacts directly with
PVR at cell junctions and promotes monocyte transendo-
thelial migration (TEM) by acting specifically during the
diapedesis step.
 
Materials and Methods
 
Endothelial Cells.
 
Human umbilical vein endothelial cells (HU-
VECs) were harvested from umbilical cord veins, pooled, and
established as primary cultures in EBM2 medium (Cambrex). Pri-
mary HUVEC cultures were serially passed, maintained in EBM2
medium, and used before the fifth passage. The Nalm6 cell line
was cultivated in RPMI 1640 medium, supplemented with 10%
FCS, 2 mM glutamine, 100 U/ml penicillin, and 50 
 
 
 
g/ml strep-
tomycin. All cells were cultivated at 37
 
 
 
C in an air 5% CO
 
2
 
 at-
mosphere at constant humidity.
 
Isolation of PBMCs.
 
PBMCs were purified from healthy blood
donors or from cytaphereses. Samples were diluted 1:2 or 1:10 in
PBS, respectively, layered over Ficoll separation medium (Lym-
phoprep; Axis-Shield), and centrifuged at 2,000 revolutions/min
for 20 min at room temperature to remove erythrocytes and
PMNs. PBMCs were collected at the interface and washed twice
with PBS.
 
Antibodies.
 
mAbs against human DNAM-1 (FS123 and
KRA236) were described previously (2). Anti–Nectin-1 (R1.302
[IgG1]), Nectin-2 (R2.477 [IgG1] and L14 [IgG2a]), Nectin-4
(N4.40 [IgG1]), PVR (PV.404, L95, M5A10, and M2C24
[IgG1]) were described previously (2, 7, 12, 22, 23). Anti-PVR
D171 (IgG1) mAb was purchased from Neomarkers. Anti-
CD146 mAb (clone F4-5H7) was provided by F. Dignat-George
(Faculté de Pharmacie, Marseille, France).
Murine monoclonal anti–VE-cadherin (clone 75; Transduc-
tion Laboratories), anti–platelet–endothelial cell adhesion mole-
cule 1 (PECAM-1)/CD31 (clone JC/70A; DakoCytomation),
rabbit polyclonal anti–
 
 
 
-catenin (Zymed Laboratories) were pur-
chased from commercial sources. Anti-CD99 (clone 12E7) mAb
was provided by A. Bernard (Institut National de la Santé et de la
Recherche Medicale, Nice, France). Anti-CD11a mAb (clone
25.3.1 [IgG1]) was provided by D. Olive (Institut National de la
Santé et de la Recherche Medicale, Marseille, France). Anti-
CD34 (clone Immu133 [IgG1]), anti–CD14–PE, anti–CD14-
FITC (clone RMO52), and isotypic controls were purchased
from Beckman Coulter and Immunotech. Alexa-488–labeled
goat anti–mouse antibody, and TRITC-labeled goat anti–rabbit
antibody were obtained from Molecular Probes. Anti-CD146
and anti–VE-cadherin mAbs were labeled with a Zenon mouse
Ig labeling kit (Alexa Fluor 546) following the instructions of the
manufacturer (Molecular Probes). PE-labeled goat anti–human
Fc fragment antibody were obtained from Beckman Coulter and
Immunotech. Purification of Fab fragments was achieved by pa-
pain treatment as recommended by the manufacturer (Pierce
Chemical Co.). Purity, assessed on Coomassie blue–stained
SDS-PAGE, was 
 
 
 
95%. Fab fragments were validated by flow
cytometry.
 
Production and Purification of Soluble Forms of Nectins and
DNAM-1.
 
Nectins–Fc constructions and productions have
been described previously (7). All plasmids were purified with an
endotoxin-free kit (QIAGEN), sterilized through a 0.22-
 
 
 
m fil-
ter, aliquoted, and stored at 
 
 
 
20
 
 
 
C.
The sequence coding for the extracellular portion of DNAM-1
receptor (nucleotide 181-951; GenBank/EMBL/DDBJ acces-
sion no. U56102) was amplified starting from the pcDNA3.1
TOPO DNAM-1 plasmid using the following primers: 5
 
 
 
-
ACGCGTCGACAACCAGCCTTTCAAACAG-3
 
 
 
 (DNAM-1
SalI up) and 5
 
 
 
-CGGGATCCTGGTTATCGGTTTTACCC-
3
 
 
 
 (DNAM-1 BamHI dw). Amplification was performed with
Vent DNA Polymerase (New England Biolabs, Inc.) for 20 cy-
cles (30 s at 95
 
 
 
C, 30 s at 58
 
 
 
C, and 30 s at 72
 
 
 
C) followed by a
7-min elongation step at 72
 
 
 
C. The 771-bp PCR product was
digested with SalI and BamHI restriction enzymes and sub-
cloned in the SalI-BamHI–digested pRB1-2B4Fcmut vector
(provided by M. Falco, Istituto Giannina Gaslini, Genova, Italy)
in frame with the sequence coding for the human IgG1 portion,
which was mutagenized to obtain a mutated Fc that does not
bind to Fc receptors. To ensure that the correct DNAM-1 se-
quence was in frame with the human IgG1, the nucleotidic se-
quence was performed. The pRB1-DNAM-1Fcmut construct 
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was stably transfected into the HEK293 cell line (human embry-
onic fibroblast) using Fugene 6 (Roche). Supernatants were col-
lected from the cell transfectant cultured in DMEM/10% ultra-
low IgG FCS (Invitrogen), and the DNAM-1–Fc molecule was
purified by affinity chromatography using protein A–Sepharose
4 Fast Flow (Amersham Biosciences). Purified protein was
checked by SDS-PAGE followed by silver staining and ELISA
using DNAM-1–specific mAbs.
 
ELISA.
 
A sandwich ELISA was used to define the region of
PVR recognized by the anti-PVR mAbs PV.404, D171, M5A10,
L95, and M2C24. 96-well trays were coated with an antibody
against the human Fc fragment (Sigma-Aldrich) at 10 
 
 
 
g/ml. Af-
ter saturation of wells with PBS containing 1% BSA, 10
 
 
 
9
 
 M of
PVR-vcc-Fc or PVR-v-Fc was reacted with 2.5 
 
 
 
g/ml of the
different mAbs followed by an incubation with a 1/2,000 dilution
of a peroxidase-labeled goat anti–mouse and revealed with the
One Step ABTS (Pierce Chemical Co.). Optical density was read
at 405 nm.
 
In Vitro Binding Studies.
 
In vitro physical interaction studies
between PVR–DNAM-1 and Nectin-2–DNAM-1 were per-
formed as follows. Ultrasorb 96-well trays (Nunc) were incubated
overnight at 4
 
 
 
C with 1 
 
 
 
g/ml of goat anti–human Fc affinity
purified serum (Sigma-Aldrich). After three washes with PBS
containing 0.5% of Tween 20, wells were incubated with PBS
containing 1% BSA. After three washes, 10
 
 
 
7
 
 M of different chi-
meric-Fc proteins (BT3-Fc, Nec3-Fc, and DNAM-1–Fc) were
incubated for 2 h at 37
 
 
 
C. After washes, free anti–human-Fc anti-
bodies were blocked with PBS containing 100 
 
 
 
g/ml of human
immunoglobulin (Novartis) for 1 h at 25
 
 
 
C. Biotinylated PVR-
Fc or Nec2-Fc (10
 
 
 
7
 
M) was incubated for 2 h at 37
 
 
 
C in the ab-
sence of Ca
 
2
 
 
 
. After three washes, 2 
 
 
 
g/ml streptavidin peroxi-
dase (Sigma-Aldrich) was incubated for 1 h at 37
 
 
 
C. After five
washes, binding was assessed by incubation with the One-Step
ABTS substrate (Pierce Chemical Co.). Optical density was read
at 405 nm.
 
Immunohistochemistry.
 
Immunodetection of Nectin-2, PVR,
and PECAM-1–CD31 were performed on 5-
 
 
 
m frozen sections
on human placenta or human normal skin using different concen-
trations of mAbs. Specimens were processed with the Universal
Kit ChemMate according to the manufacturer’s recommenda-
tions, counterstained for 5 min in Harris hematoxylin, and
mounted in glycergel mounting medium (DakoCytomation).
Figure 1. Analysis of the cell surface expression of
DNAM-1, PVR, and Nectin-2 on monocytes and pri-
mary vascular endothelial cells. (a) Fresh PBMCs were
gated on monocytes on the basis of both size and gran-
ularity. Cells were analyzed by two-color immunoflu-
orescence and FACS® analysis with anti-CD14 mAb in
combination with anti–DNAM-1 (FS.123), anti-PVR
(PV.404), or anti–Nectin-2 (R2.477) mAbs followed
by FITC- or PE-conjugated goat anti–mouse second
reagents. (b) HUVECs were analyzed by one-color
immunofluorescence and FACS® analysis with anti–
DNAM-1 (FS123), anti-PVR (PV.404), anti–Nectin-2
(R2.477), or anti–PECAM-1 (JC/70A) mAbs followed
by FITC-conjugated goat anti–mouse second reagents.
Gray profiles indicate cells incubated with the second
reagent only. We previously controlled that trypsin
treatment does not affect cell surface expression of
Nectins. Similar results were obtained when HUVECs
were detached with 0.02% (wt/vol) disodium EDTA
in PBS. (c) Localization of Nectin-2 and PVR on pri-
mary endothelial cells. HUVECs were fixed; incubated
with 2  g/ml of anti–Nectin-2 (R2.477), anti-PVR
(PV.404), and anti–PECAM-1 (JC/70), followed by
Alexa-488–labeled goat anti–mouse second reagent;
and analyzed by immunofluorescence microscopy.
Staining was similar on live cells (not depicted). (d)
HUVECs were fixed, permeabilized, and stained with
the anti–Nectin-2 (R2.477) mAb and the anti– -cate-
nin rabbit antiserum followed by Alexa-488–labeled
goat anti–mouse antibody and TRITC-labeled goat
anti–rabbit second reagents, respectively. Cells were
analyzed by immunofluorescence microscopy. 
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Immunofluorescence Microscopy.
 
HUVECs were grown on 13-
mm round glass coverslips as a confluent monolayer to reach op-
timal cell-to-cell contact. Cells were fixed with 3.7% paraformal-
dehyde in PBS for 20 min at room temperature. After blocking
aldehydes with 50 mM NH
 
4
 
Cl for 10 min at room temperature,
fixed cells were incubated with either 0.2% gelatin in PBS, or
with 0.2% gelatin and 0.075% saponin (all obtained from Sigma-
Aldrich) in PBS for 20 min. Fixed samples were first labeled with
the appropriate antibodies for 60 min at room temperature and
incubated with secondary antibodies in the same conditions. Al-
ternatively, immunofluorescence analysis on filters by conjugat-
ing mAbs with the 546-nm–labeled IgG2b isotype-specific Ze-
non Fab (Molecular Probes). Finally, samples were washed,
mounted onto slides, embedded with mounting medium (Dako-
Cytomation), and visualized using a confocal microscope (Leica).
Images were processed using the Adobe Photoshop software. In
some experiments, staining was performed on live cells followed
by paraformaldehyde fixation.
 
Flow Cytometry.
 
HUVECs were trypsinized and resuspended
after centrifugation in 5% FCS containing PBS. In some experi-
ments, HUVECs were detached with 0.02% (wt/vol) disodium
EDTA in PBS. Cells were incubated with 2–10 
 
 
 
g/ml of the ap-
propriate antibody and with a PE-labeled goat anti–mouse anti-
body (Immunotech).
 
TEM Assay.
 
HUVEC subcultures were removed with tryp-
sin/EDTA and plated onto 0.1% gelatin (Sigma-Aldrich)-coated
Costar transwells (5-
 
 
 
m pore size and 6.5-mm diameter), at 3.5 
 
 
 
10
 
4
 
 cells/well. Endothelial cell monolayers were grown to
confluency for 4 d at 37
 
 
 
C. 5 
 
 
 
 10
 
5
 
 PBMCs were loaded on each
transwell. We assessed the permeability of HUVEC monolayers
using 38,900 D of FITC dextran at 1 mg/ml. Fluorescence was
monitored at 520 nm using a Wallac Victor fluorometer. Cell
were allowed to transmigrate for 1 h at 37
 
 
 
C. Migrated mono-
cytes were recovered from the bottom of the well and mixed
with 10
 
5
 
 calcein-labeled Nalm6 cells. Cells were centrifuged and
incubated with an anti–CD14-PE antibody for 15 min. Finally,
cells were analyzed with flow cytometry. Each condition was
performed in quadruplicate. In some experiments, assays were
performed in the presence of 10 
 
 
 
M polymyxin B.
 
Results
 
DNAM-1 Is Highly Expressed On Monocytes, Whereas Its
Ligands PVR and Nectin-2 Are Expressed at Intercellular Junc-
tions in Vascular Endothelial Cells.
 
We demonstrated recently
that PVR and Nectin-2 are cell surface ligands of DNAM-1
that specifically induce NK cell–mediated cytolytic activity
against tumor cell targets (2). In the present paper, we in-
vestigated the role of the interactions between DNAM-1
and its ligands on normal cells. Most leukocytes were
shown to express DNAM-1 (1). PVR and Nectin-2 are
cell adhesion molecules specifically expressed at E-cad-
herin–based AJs in epithelial cells. AJs are structurally and
functionally similar in endothelial cells because VE-cad-
herin is the major component of endothelial AJ-mediating
homophilic interaction between adjacent cells. In a first set
of experiments, we analyzed the expression of DNAM-1,
PVR, and Nectin-2 on leukocytes and endothelial cells. As
shown in Fig. 1 a, low surface densities of PVR and Nec-
tin-2 were detected on monocytes. Nectin-3 and Nectin-4
were not detected on monocytes (unpublished data). Ac-
cording to previous data, different leukocyte subsets, in-
cluding monocytes (Fig. 1 a), highly express DNAM-1 (1).
The expression of DNAM-1, PVR, and Nectin-2 was as-
sessed on primary endothelial cells by both flow cytometry
and immunofluorescence microscopy. DNAM-1 is not or
just faintly expressed on HUVECs, whereas PVR and
Nectin-2 are highly expressed at levels similar to PE-
CAM-1 (Fig. 1 b). Moreover, both PVR and Nectin-2 are
mostly expressed at endothelial cell junctions on HUVECs,
similar to PECAM-1 (Fig. 1 c). They show an extremely
similar distribution at cell borders compared with the VE-
cadherin cytoplasmic partner 
 
 
 
-catenin (Fig. 1 d). Finally,
PVR and Nectin-2 as well as PECAM-1 are expressed on
endothelial cells of placental blood vessels (Fig. 2 a, black
arrows). In particular, in some sections and in accordance
Figure 2. Expression of Nectin-2 and PVR on hu-
man placenta and skin. Frozen sections of placenta (a)
and normal skin (b) were analyzed by immunohis-
tochemistry with 5  g/ml anti–Nectin-2 (R2.477), 5
 g/ml anti-PVR (D171), or 2  g/ml anti–PECAM-1
(JC/70) mAbs as described in Materials and Methods.
mAb-specific staining was observed on endothelial cells
of the placenta and skin blood vessels (black arrows)
and at cell-to-cell junctions (white arrow). Staining
specificity was assessed by an irrelevant isotype match
control mAb and also by the fact that other cell types in
the section were negative for Nectin-2 and PVR. Bars,
20  m. 
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with their intercellular localization on HUVECs (Fig. 1 c),
staining is observed at cell-to-cell contacts (Fig. 2 a, white
arrows). PVR and Nectin-2 are also expressed in vessels
from normal skin (Fig. 2 b). These data show that PVR and
Nectin-2 are two new junctional molecules expressed at
vascular endothelial cell junctions, whereas their counter
receptor, DNAM-1, is expressed on monocytes.
 
PVR Is the Major DNAM-1 Counter-Receptor on Endothe-
lial Cells.
 
Our data showed that DNAM-1, PVR, and
Nectin-2 are expressed on monocytes. Potential interac-
tions between these molecules with PVR and Nectin-2 on
endothelial cells were assessed. To this end, chimeric mole-
cules formed with the whole ectodomain of these mole-
cules fused to the Fc fragment of human IgG1; namely
NAM-1–Fc, PVR-Fc, and Nec2-Fc were analyzed for
their binding on endothelial cells. Nec2-Fc and PVR-Fc
do not significantly bind to HUVECs when compared
with an irrelevant control (Fig. 3 a, N4vtr-Fc). Alternately,
DNAM-1–Fc strongly binds to HUVECs. Confocal mi-
croscopy shows that DNAM-1–Fc, but not Nec2-Fc, spe-
cifically stains and delineates endothelial cell junctions,
which suggests that DNAM-1 ligands are junctional mole-
cules (Fig. 3 b). This is in agreement with the localization
of PVR and Nectin-2 at cell junctions (Fig. 1).
We analyzed the binding of DNAM-1–Fc relative to
the expression of PVR or Nectin-2 molecules ectopically
expressed in CHO cells (Fig. 4 a). We observed that 1.5
 
 
 
M DNAM-1–Fc strongly binds to PVR-expressing
cells, but binds less efficiently to Nectin-2–expressing
CHO cells, whereas it does not bind to control CHO
cells. These data suggest that, under these conditions,
DNAM-1 preferentially binds to PVR. Of note, DNAM-
1–Fc binding was never detected on other Nectin-
expressing CHO cells (i.e., Nectin-1, -3, and -4; un-
published data). Even though these data strongly suggest a
direct interaction, binding was analyzed by means of
recombinant molecules. Both PVR-Fc and Nec2-Fc
strongly bind to coated DNAM-Fc and not to the irrele-
vant control (Fig. 4 b). Of note, both PVR-Fc and Nec2-
Fc also bind to coated Nec3-Fc as described previously
(Fig. 4 b and reference 7). Interestingly, PVR-Fc binding
to DNAM-Fc is stronger than Nec2-Fc, which confirms
our FACS
 
®
 
 analysis. Altogether, these data highlight for
the first time the direct DNAM-1–PVR and DNAM-1–
Nectin-2 interactions.
DNAM-1–Fc binding was performed on endothelial
cells. To discriminate between PVR, Nectin-2, or still-un-
identified junctional ligands expressed by these cells, anti-
PVR and anti–Nectin-2 mAbs were tested for their ability
to block DNAM-1–Fc binding on HUVECs. Thus, HU-
VECs, either preincubated with anti-PVR or anti–Nectin-
2 mAbs and used alone, in combination, or with control
mAbs, were analyzed by double fluorescence for DNAM-
1–Fc binding used at 1.5 
 
 
 
M (Fig. 5 a). DNAM-1–Fc
binding to HUVECs is not significantly reduced by anti–
Nectin-2 mAb preincubation, and is similar to controls
without mAb or with the irrelevant anti–Nectin-1 mAb.
On the contrary, anti-PVR mAb alone nearly induces a full
inhibition (97%) of DNAM-1–Fc binding. Using immu-
nofluorescence microscopy, we show that DNAM-1–Fc
binding to endothelial cell junctions was not modified by
anti–Nectin-1 and anti–Nectin-2 mAbs, but was strongly
inhibited by anti-PVR mAbs. This strengthens the specific-
ity of DNAM-1 binding to PVR, expressed at interendo-
thelial junctions (Fig. 5 b). To extend and confirm these
observations, five different anti-PVR mAbs were tested for
their ability to interfere with DNAM-1–Fc binding on
HUVECs. As shown in Fig. 5 c, all of them efficiently in-
hibit DNAM-1–Fc binding. The various anti-PVR mAbs
were mapped by ELISA assay (Fig. 5 d). PV.404, M5A10,
and M2C24 react with the IgC-like domain of PVR,
whereas D171 and L95 are directed against the IgV-like
domain of the molecule. These results suggest that both V
and C Ig-like domains of PVR are involved in the interac-
Figure 3. DNAM-1 recognizes junc-
tional ligands expressed on endothelial cells.
(a) HUVECs were analyzed by one-color
immunofluorescence and FACS® analysis
with Nec2-Fc, PVR-Fc, DNAM-1–Fc, and
N4vtr-Fc (negative control) followed by
FITC-conjugated goat anti–human second
reagents. Gray profiles indicate cells incu-
bated with the second reagent only. All sol-
uble proteins were used at 20  g/ml. Simi-
lar results were obtained when HUVECs
were detached with 0.02% (wt/vol) diso-
dium EDTA in PBS. (b) Immunofluores-
cence microscopy analysis of HUVECs us-
ing 20  g/ml DNAM-1–Fc followed by
FITC-conjugated goat anti–human second
reagents. No staining was revealed with
Nec2-Fc. The DNAM-1–Fc staining delin-
eates the junctional systems between adja-
cent cells suggesting that DNAM-1 interacts
with ligands localized at endothelial cell
junctions. Similar results were obtained on
live confluent HUVECs (not depicted). 
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tion with DNAM-1. Altogether, our results demonstrate
that DNAM-1 interacts directly and specifically with PVR
on endothelial cells, and that this interaction occurs at en-
dothelial cell junctions.
 
PVR and DNAM-1 Are Involved in Monocyte Transmigra-
tion.
 
Endothelial junctions have been described as key
regulators of blood vessel permeability. Consistent with
their distribution at endothelial cell junctions, PVR and
Nectin-2 may thus participate in the events that regulate
leukocyte extravasation through the endothelium. Having
demonstrated that PVR is the major ligand of DNAM-1
on endothelial cells, we investigated the potential role
of the PVR–DNAM-1 interaction during the TEM of
monocytes. We controlled that anti-PVR mAbs readily ac-
cess to the junctions of live HUVECs (not depicted), and
we showed that anti-PVR mAbs do not modify the endo-
thelial permeability (not depicted) and the endothelial
integrity (see Fig. 7). Their ability to block monocyte trans-
migration in an in vitro TEM model was explored. Anti-
PVR mAbs induced a significant blocking in monocyte
transmigration when compared with isotype-matched irrel-
evant antibodies (Fig. 6 a, anti-CD34 and anti–Nectin-4
mAbs). Inhibition of monocyte transmigration was ob-
served with five different anti-PVR mAbs (blockade be-
tween 60 and 80%) and was similar to that obtained with
anti-CD99 mAb (Fig. 6 a, 12E7) and anti–LFA-1/CD11a
(Fig. 6 b, 25.3.1), taken as positive controls (24, 25). Tar-
geting of DNAM-1 with two different mAbs also strongly
inhibits monocyte transmigration to 80%. Fab fragments of
anti-PVR (mAbs) and anti–DNAM-1 (mAbs) efficiently
Figure 4. PVR and Nectin-2 directly
bind to DNAM-1. (a) CHO/K cells either
nontransfected or transfected with PVR or
Nectin-2 cDNAs were analyzed by FACS®
analysis with anti-PVR (L95) or anti–Nec-
tin-2 (L14) mAbs, followed by a PE-conju-
gated goat anti–mouse second reagents
(left). CHO/K: gray line, isotype matched
mAb; black line, L95 mAb; and dashed line,
L14 mAbs. CHO/K transfectants: gray line,
isotype matched mAb and black histogram,
L95 and L14 mAbs. Binding of DNAM-1–
Fc at 1.5  M on CHO/K cells was revealed
by PE-conjugated goat anti–human second
reagents (right): (gray line) incubation with
the second reagent.; (black histogram) incu-
bation with 1.5  M DNAM-1–Fc. (b, left)
PVR and Nectin-2 directly bind to Nectin-3.
(right) To analyze PVR and Nectin-2 inter-
actions with DNAM-1, biotinylated PVR-
Fc and Nectin-2–Fc binding was measured
by ELISA on wells coated with BT3-Fc
(unrelated protein), Nectin-3–Fc (positive
control), or DNAM-1–Fc. PVR-Fc and
Nectin-2–Fc directly bind to DNAM-1–Fc
and as expected with Nectin-3–Fc. 
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inhibited TEM, as they blocked monocyte transmigration
to the same extent as mAbs (Fig. 6 a). This rules out the
possibility that inhibition may be due to Fc binding of
mAbs to monocyte Fc receptors. The inhibition of mono-
cyte TEM upon anti-PVR or anti–DNAM-1 mAb treat-
ment is due to a blockade and not a slow down, as the same
blockade was observed after a 3-h transmigration run.
When incubating anti-PVR mAbs only on HUVECs,
monocyte TEM was strongly blocked, which was not
the case with anti–DNAM-1 mAb (Fig. 6 b). Because
DNAM-1 is not or just faintly expressed on HUVECs,
these results strongly suggest that DNAM-1 on monocytes
is involved in this process. These results also suggest that
anti-PVR mAbs block monocyte at the level of TEM and
not by interfering with chemotaxis. To definitively dem-
onstrate that mAbs did not inhibit chemotaxis, anti-PVR
and anti–DNAM-1 Fabs were tested in a chemotaxis assay.
No inhibition was noted when monocytes were incubated
with both Fabs (Fig. 6 c). Altogether, our results demon-
strate that endothelial PVR interacts with DNAM-1 on
monocyte to ensure monocyte TEM.
 
PVR and DNAM-1 Take Part in the Diapedesis Process.
 
Transmigration is a multistep process and interfering at any
step usually leads to blocking of the whole process. Thus,
the precise step of action of PVR and DNAM-1 during
monocyte transmigration was investigated. To distinguish
between a blockade at the step of adhesion or during dia-
pedesis itself, in vitro adhesion experiments were per-
formed under static conditions with monocytes on HU-
VECs. No blockade of monocyte adhesion with anti-PVR
mAbs was observed (not depicted), which was consistent
with PVR localization at cell junctions (Fig. 1 a). The pre-
cise step at which monocytes were blocked during the
TEM process was examined by the simultaneous staining of
monocytes and endothelial cells. Cross-sections of the en-
dothelial monolayer, analyzed in the z-plane, showed that,
in the absence of mAbs, monocytes transmigrate through
the HUVEC monolayer. After 1 h, some of them were still
observed finishing their transmigration through the lowest
part of the filter below the endothelial cell monolayer (Fig.
7 a, left). When incubating HUVECs and monocytes with
anti-PVR mAbs, monocytes were blocked at the apical
surface of the endothelium (Fig. 7 a, right). Moreover,
monocytes were arrested over intercellular junctions as
demonstrated by the staining with an anti–VE-cadherin
mAb (Fig. 7 b, XY plane, arrow). Interestingly, monocyte
membranes slightly protrude inside the intercellular junc-
tions as shown by the tight localization between CD14 and
VE-cadherin staining (Fig. 7 b, XZ plane, arrow). These
data indicate that PVR is involved in the process of mono-
cyte diapedesis rather than in the step of adhesion, as re-
ported previously for PECAM-1 (24).
Figure 5. PVR is the major DNAM-1 ligand on en-
dothelial cells. (a) Inhibition of DNAM-1–Fc binding
by different anti-Nectin mAbs. HUVECs, either un-
treated or preincubated with anti-PVR (L95) and anti–
Nectin-2 (L14) mAbs used alone or in combination,
were analyzed by two-color immunofluorescence and
FACS® analysis for DNAM-1–Fc binding used at 1.5
 M. FITC-conjugated goat anti–mouse or PE-conju-
gated goat anti–human were used as second reagents.
(b) Similar experiments were performed by immuno-
fluorescence microscopy on confluent HUVECs. 1.5
 M DNAM-1–Fc binding at endothelial junctions was
not affected by preincubation with anti–Nectin-1
(R1.302) or anti–Nectin-2 (L14) mAbs. Anti-PVR
(L95) mAb preincubation strongly affects the DNAM-
1–Fc binding at endothelial junctions. mAbs were used
at 20  g/ml. (c) HUVECs, preincubated with the dif-
ferent anti–Nectin-2 (gray bars) or anti-PVR (black
bars) mAbs, were analyzed by FACS® analysis for
DNAM-1–Fc binding used at 0.15  M followed by
FITC-conjugated goat anti–human second reagents.
Untreated HUVECs stained with N4vtr-Fc were used
as negative control (white bars). The value 100% corre-
sponds to DNAM-1–Fc binding in the presence of the
irrelevant anti–Nectin-1 (R1.302) mAb. (d) The dif-
ferent anti-PVR mAbs were mapped by ELISA using
PVR-Fc molecules. PVR-vcc-Fc is constituted by the
full-length ectodomain of PVR, whereas PVR-v-Fc is
only constituted by the V domain of PVR. 
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The site of monocyte blockade was also analyzed af-
ter anti–DNAM-1 treatment of monocytes. In this case,
monocytes were also blocked at the surface of endothelial
cells and in particular over intercellular junctions, at the
same site as PVR (Fig. 7 c). Altogether, our results strongly
suggest that DNAM-1–PVR interactions occur during the
diapedesis phase to promote monocyte TEM.
 
Discussion
 
We described recently that DNAM-1 is involved in NK
cell–mediated target cell killing of tumor cells by interact-
ing specifically with PVR and Nectin-2 (2). Although
PVR and Nectin-2 are expressed on tumor cell lines, they
are also widely expressed on normal cells that are protected
from NK cell–mediated lysis by their expression of HLA
class I molecules. The aim of our analysis was to clarify the
role of DNAM-1 interactions with its ligands in a normal
setting. Nectins are homophilic and heterophilic cell adhe-
sion molecules involved in several cell recognition pro-
cesses, including the formation of cell junctions between
epithelial cells and between neurons (10). For the first time,
we demonstrate that PVR is the major ligand of DNAM-1
on endothelial cells. Our results highlight a role for DNAM-1
and PVR during leukocyte extravasation because they ap-
pear to be crucial for monocyte migration through endo-
thelial junctions during the diapedesis step. This hypothesis
is supported by the following observations. First, DNAM-1
binds specifically to the endothelium at cell junctions
where PVR is expressed with a distribution similar to Nec-
tin-2 and 
 
 
 
-catenin. Second, targeting endothelial PVR,
but not Nectin-2, inhibits DNAM-1 binding to endothe-
lial cells. Third, mAb-mediated masking of DNAM-1 or
PVR almost abrogates monocyte TEM. Last, during the
TEM process, anti–DNAM-1 or anti-PVR mAb treatment
blocks monocytes at the surface of endothelial cells specifi-
cally over intercellular junctions, similar to treatment with
a blocking mAb to PECAM-1 (26).
DNAM-1 has been described previously to be cis-associ-
ated with LFA-1 in T cells (27). For the first time, we show
that PVR and also Nectin-2 can bind directly to DNAM-1
and that this binding is independent of LFA-1. We found
that Nectin-2–DNAM-1 interaction was reproducibly lower
than PVR–DNAM-1 interaction according to our previ-
ous results (2). This observation is probably related to a dif-
ference of affinity. Our results show that DNAM-1 does
not interact with endothelial Nectin-2 despite its high level
of expression on HUVECs. This suggests that the interac-
tion between DNAM-1 and PVR and/or Nectin-2 may be
regulated by complex mechanisms in endothelial cells. We
Figure 6. PVR and DNAM-1 contribute to
monocyte transmigration. Monocyte transmi-
gration through the HUVEC monolayer was
performed in the presence of 20  g/ml of the
indicated anti-PVR or anti–DNAM-1 (sodium
azide free) mAbs, and 250 ng/ml MCP-1 was
added to the lower chamber. Each measure-
ment was done in quadruplicate. The results are
representative of three independent experi-
ments. (a) The N4.40 mAb that does not bind
monocytes and HUVECs and Immu-133 mAb
that strongly binds to HUVECs were used as
isotype-matched irrelevant antibodies. Anti-
CD99 mAb 12E7 was used as an inhibitory
control. The value 100% corresponds to the
number of monocytes that migrate in the pres-
ence of the Immu-133 mAb; FACS® analysis
confirmed that almost every monocyte of the
PBMC suspension transmigrates under this
condition. Fab fragments of PV.404 or FS123
mAbs were used at 20  g/ml. (b) Anti-CD11a
mAb was used as a positive control. In this ex-
periment, anti-PVR and anti–DNAM-1 mAbs
were incubated on both monocytes and HU-
VECs (M E) or only on endothelial cells (E).
In the latter condition (E), mAbs were incu-
bated for 30 min with HUVECs and washed
with fresh medium. Monocytes were incu-
bated, and TEM was processed as in a. In this
experiment, the different antibodies used were
treated with 10  M polymyxin B. (c) Chemo-
taxis assay. Chemotaxis, in response to 250 ng/
ml MCP-1, was assessed for 1 h on costar
transwells (5- m pore size and 6.5-mm diame-
ter). Experimental conditions were similar to
the TEM assay, except that filters were not lay-
ered with endothelial cells. Fabs were incubated
through the process of migration.Reymond et al. 1339
described previously two isoforms of Nectin-2 ( , the short
isoform, and  , the long isoform) that differ by their trans-
membrane and cytosolic regions and can homo- or het-
erodimerize at the cell surface (12). Taken individually, we
found that these two isoforms equally bind DNAM-1–Fc
(unpublished data) and are both expressed in HUVECs
(unpublished data). Thus, the lack of interaction between
DNAM-1 and endothelial Nectin-2 may not be related to
a peculiar expression of Nectin-2 isoform in these cells.
These data suggest that the DNAM-1 binding domain on
Nectin-2 might not be functional in resting HUVECs
by being in a low affinity state related to an absence of
cis-dimerization or to a nonactive conformational state.
DNAM-1 interaction with PVR is blocked by all anti-
PVR mAbs tested. Some of these mAbs were also shown
to inhibit DNAM-1–mediated NK cell lysis (2). Interest-
ingly, these mAbs recognize either the V or the C domains
of PVR, which suggests that they both contribute to the
interaction with DNAM-1. These data contrast with those
already described for Nectin transinteractions; indeed, we
showed previously that V-to-V domain interactions play a
prominent role during Nectin-1–Nectin-3 and Nectin-1–
Nectin-4 transinteractions (7, 23).
Thus, today, PECAM-1 (26, 28–30), CD99 (24), JAMs
(31–33), and now Nectins constitute four molecular fami-
lies of endothelial cell adhesion molecules that have been
described to participate to leukocyte diapedesis. Even
though they may act together in some circumstances, these
molecules may assume peculiar functions respective to their
expression pattern, their spatio-temporal behavior at the
intercellular junctions, or their role to deliver specific sig-
nals that regulate diapedesis.
It has been shown that NK cells migrate to injured tis-
sues where they kill tumor or virus-infected target cells and
interact with dendritic cells (34). It is conceivable that
DNAM-1 molecules may regulate both migration of NK
cells and NK cell–mediated cytolytic activity, depending
on the level of HLA class I molecules expressed by encoun-
tered target cells. As described for JAMs (35), Nectins ap-
pear to be differentially expressed in endothelia. We ob-
served that Nectin-2, but not PVR, is expressed on high
endothelial venules (unpublished data). This suggests that
Nectin-2 may take part in the process of lymphocyte hom-
ing to secondary lymphoid organs. Molecular basis of leu-
kocyte diapedesis has only begun to be understood; recent
studies highlighted that CD99 could act downstream of
PECAM-1 during the diapedesis process (24), and that PE-
CAM-1 could guide leukocyte diapedesis by recycling
from vesicles to the zone of transmigration (30). Our
immunofluorescence analysis shows that mAb-mediated
disruption of PVR–DNAM-1 interactions induces a block-
ade of monocytes similar to that observed upon anti–
Figure 7. Blocking PVR–DNAM-1 transinteractions arrest
monocytes over intercellular junctions at the apical surface of
endothelial cells. Staining was performed after a 1-h migration
run on transwell filters. (a) Monocyte migration was run in the
absence (control) or the presence of anti-PVR mAb (PV.404)
at 20  g/ml. Cells were fixed, stained with 10  g/ml anti-
CD146 (previously conjugated to the 564-nm–labeled IgG1
isotype-specific Zenon Fab) and 2  g/ml anti-CD14 (FITC-
conjugated) mAbs to homogeneously stain endothelial cells
and visualize monocytes, respectively. A series of images was
recorded simultaneously in the XY and XZ planes. The results
are representative of three independent experiments. (left)
Monocytes untreated (control) are ending their transmigration
and can be seen through the filter. (right) Upon anti-PVR
treatment, monocytes are blocked over the endothelial cell
monolayer. (b) Migration was run in the presence of 20  g/ml
of anti-PVR mAb (PV.404). Cells were fixed and stained with
10   g/ml anti–VE-cadherin (previously conjugated to the
564-nm–labeled IgG1 isotype-specific Zenon Fab) and 2  g/
ml anti-CD14 (FITC-conjugated) mAbs to visualize endothe-
lial junctions and monocytes, respectively. (top) White arrows
indicate the position of blocked monocytes over the endothe-
lial cell junctions in the XY plane. (bottom) XZ plane cross-
section view according to the dotted line arrow in the XY
plane. White arrowheads indicate the junctional staining of
VE-cadherin. Red arrow marks the protruding monocyte
membrane close to junctional VE-cadherin. (c) Monocyte
transmigration through the HUVEC monolayer was per-
formed as in b. Anti–DNAM-1 mAb (FS123) was used at 20
 g/ml. XZ plane cross-section view of monocytes arrest over
the endothelial cell junctions as described in panel a. The re-
sults are representative of three independent experiments.DNAM-1 and PVR Regulate Monocyte Diapedesis 1340
PECAM-1 treatment (i.e., early during the diapedesis pro-
cess; Fig. 7). This strongly suggests that PVR and DNAM-1
may take part in the first events of diapedesis together with
PECAM-1. Different papers showed that Nectins, JAM-A,
and PECAM-1 share common cytoplasmic partners that
connect them to the cadherin system; Nectins and JAM-A
interact with  -catenin via the F-actin binding protein
AF-6 (36), and PECAM-1 directly interacts with  -catenin
(37). Thus, it is possible that engagement of leukocytes
through intercellular endothelial space triggers these mole-
cules, which subsequently regulate VE-cadherin homo-
philic adhesion strength and induce its removal from cell-
to-cell contact sites. Deciphering the sequence by which
PECAM-1, CD99, JAMs, and Nectins play their respective
role to the VE-cadherin gap formation will lead to a better
understanding of the mechanisms that regulate leukocyte
migration through endothelial cells.
Interestingly, cell adhesion molecules involved in the
step of diapedesis have different behavior during the in-
flammation process. Among them, JAM-A is redistributed
away from cell junctions to the apical pole upon endothe-
lial activation (38). Recently, Ostermann et al. showed that
endothelial luminal expression of JAM-A contributes to the
LFA-1–dependent leukocyte recruitment (33). Nectins re-
cruit JAM-A and enable its correct targeting to tight junc-
tions in epithelial cells (36). Thus, we can postulate that
Nectin-2, PVR, and JAM-A could form a molecular com-
plex of adhesion molecules on endothelial cells that interact
with DNAM-1 and LFA-1 during monocyte recruitment.
It will be interesting to analyze the behavior of PVR and
Nectin-2 upon endothelial activation.
Beyond this role, Nectins are expressed during develop-
ment and in tumor cells; their potential role in tumor pro-
gression as well as in neovascularization and angiogenesis
also deserve further investigation.
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